title: Polaprezinc attenuates Helicobacter pylori-associated gastritis in Mongolian gerbils.
abstract: BACKGROUND
  The ammonia-monochloramine system plays an important role in Helicobacter pylori-associated gastric mucosal injury. Polaprezinc, a new antiulcer agent, has a scavenging action against monochloramine. The aim of the experiment was to investigate the inhibitory effects of polaprezinc on the H. pylori-induced gastritis in Mongolian gerbils.
  
  
  METHODS
  Mongolian gerbils fasting for 24 hours were orally given culture broth containing 2-4 x 10(8) colony-forming units of H. pylori ATCC 43054 per milliliter. From 4 hours after inoculation until the end of the experiment, gerbils were given chow pellets with or without 0.02% polaprezinc. All gerbils were killed 12 weeks later. The grades of H. pylori density and histologic features of gastritis were evaluated in accordance with the Updated Sydney System. The scavenging effect of polaprezinc on monochloramine was investigated spectrophotometrically.
  
  
  RESULTS
  Polaprezinc had little or no influence on the H. pylori density in both pyloric and fundic mucosae. However, it significantly attenuated the development of polymorphonuclear neutrophil activity, mononuclear infiltration, and surface epithelial erosion in both pyloric and fundic mucosae compared with those of the control group. H. pylori inoculation significantly increased the heights of both pyloric and fundic mucosae (mainly due to the increased height of foveolar hyperplasia), but polaprezinc inhibited the increase of mucosal thickness in both pyloric and fundic mucasae. No intestinal metaplasia was detected in this study. Spectrophotometric examination revealed that polaprezinc scavenged monochloramine.
  
  
  CONCLUSIONS
  Polaprezinc inhibited the development of H. pylori-induced gastritis through its scavenging action against monochloramine.
authors.affiliation: Department of Gastrointestinal Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
authors.forename: Ryu
authors.initials: R
authors.lastname: Ishihara
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Iishi
authors.forename: Noriko
authors.initials: N
authors.lastname: Sakai
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yano
authors.forename: Noriya
authors.initials: N
authors.lastname: Uedo
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Narahara
authors.forename: Kazushige
authors.initials: K
authors.lastname: Iseki
authors.forename: Tomiko
authors.initials: T
authors.lastname: Mikuni
authors.forename: Shingo
authors.initials: S
authors.lastname: Ishiguro
authors.forename: Masaharu
authors.initials: M
authors.lastname: Tatsuta
mesh_terms: D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002336:Carnosine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D002700:Chloramines / Q000737:chemistry; D004195:Disease Models, Animal; D005753:Gastric Mucosa / Q000737:chemistry / Q000473:pathology; D005756:Gastritis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D005849:Gerbillinae; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D016480:Helicobacter pylori / Q000187:drug effects*; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D013053:Spectrophotometry; D015032:Zinc / Q000737:chemistry; D017967:Zinc Compounds
chemical_list: D000897:Anti-Ulcer Agents; D002700:Chloramines; D009942:Organometallic Compounds; D017967:Zinc Compounds; C061957:polaprezinc; D002336:Carnosine; D015032:Zinc; C030816:chloramine